Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

BACKGROUND: The lack of adequate randomized clinical trials (RCT) has hindered identification of new therapies that are safe and effective for patients with primary focal segmental glomerulosclerosis (FSGS), especially in patients who fail to respond to corticosteroids and immunosuppressive therapie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Trachtman, Howard, Vento, Suzanne, Gipson, Debbie, Wickman, Larysa, Gassman, Jennifer, Joy, Melanie, Savin, Virginia, Somers, Michael, Pinsk, Maury, Greene, Tom
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2011
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3045306/
https://ncbi.nlm.nih.gov/pubmed/21310077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-12-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados